title: Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
authors.forename: Nigel
authors.initials: N
authors.lastname: Hawkes
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics; D000069579:Ranibizumab; D013222:State Medicine / Q000191:economics; D006113:United Kingdom
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab